Clinical Research Facility

Galesburg, Illinois 61401

We've found

2 trials

at this facility

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Status: Enrolling, Phase III
Updated: 12/31/1969

from

Galesburg, IL

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Status: Enrolling, Phase IV
Updated: 11/2/2015

from

Galesburg, IL

Use our guide to learn which trials are right for you!